Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28
days in ameliorating adverse ocular side effects in patients under ongoing treatment with
glaucoma medications.